Please try another search
Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Name | Age | Since | Title |
---|---|---|---|
Harry Thomas Hall | - | 2023 | MD, CEO & Director |
Grant Hummel | - | 2023 | Independent Non-Executive Director |
Katherine Ostin | - | 2023 | Independent Non-Executive Director |
Aileen Ptucha Stockburger | 61 | 2018 | Independent Non-Executive Chairman |
Daniel Spira | - | 2017 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review